tracking microbicide funding

Slides:



Advertisements
Similar presentations
R&D Financing by the Bill & Melinda Gates Foundation
Advertisements

Global Alliance for Vaccines and Immunization. n An Alliance u Traditional and new partners u Public and private sector n Partners have in common: u Situation.
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
BUSINESS YOUR BUSINESS About us Services Contact SOLUTIONS Professional SOLUTIONS GROWTH Supporting the GROWTH of Why work with us?
HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International.
Public Sector Donors Who Increased Funding for HIV Vaccine R&D in 2011 How much did donor funding increase?
Where now? Evaluation and evidence-based decision making Jodi Nelson Impact Planning and Improvement, Global Development April 13, 2009.
U.S. Science Policy Cheryl L. Eavey, Program Director
Overseeing Chicago’s 10-Yr Plan to End Homelessness Betsy Benito Chicago Department of Housing NAEH Conference 2007.
Civil Society in Decision Making for Immunization Policies: the example of National Immunization Technical Advisory Groups (NITAGs) Center for Vaccine.
ACSM MEETING A Centre for Resource Mobilization by Louise Baker, Stop TB Secretariat.
Forschungs- & Entwicklungs-Prozess
T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Sources of Support and What They Mean to the Field Dr. Duff Gillespie June 15 th, 2002 Africa SOTA, Nairobi.
Microbicide Science and Research Update Jana Caylor Bowcut, MPH Research Associate Alliance for Microbicide Development Global Campaign for Microbicides.
1 Current Funding Streams in New York State The 2008 Equity Symposium Comprehensive Educational Equity: Overcoming the Socioeconomic Barriers to School.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
Economic Impact of Centers and Institutes in Florida’s Public Universities Tim Lynch, Ph.D., Director Julie Harrington, Ph.D., Asst. Dir. Center for Economic.
September 22, 2010 Strategic Aerospace and Defence Initiative (SADI) Program Overview.
DRAFT: Budget Transparency and Country Systems December 4, 2013, Seoul Forum on Using Country Systems to Manage Climate Finance.
The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department.
Malta Council for Science and Technology Research Opportunities for SMEs Dr Brian Warrington CEO, MCST.
June 3, Vision “MUSC should be a Leading and Transformative Academic Health Center.” President Ray Greenberg, M.D., Ph.D. Academic Leadership Retreat-
The Federal Budget Process and Its Impact on the Nonprofit Sector July 21 st, 2011 Participant Call-In Number:
National Working Group on Microbicides Rectal microbicides: The political landscape Ananthy Thambinayagam, MPH Global Campaign for Microbicides Rectal.
1 Finance Clinic Climate Public Expenditure and Institutional Reviews (CPEIRs) Rakshya Thapa Regional Technical Specialist UNDP LECB Annual Global Meeting.
Influencing Change Through Advocacy at the State Level 2006 National Alliance to End Homelessness Conference Ending Homelessness: Plan, Act, Succeed.
Ministerul Mediului si Gospodaririi Apelor Session 6 - Enhancing National GEF Coordination, Communication and Outreach Developing the National Capacity.
From Mexico to Vienna: The work of the Alliance Dr Hirotsugu AIGA GHWA Coordinator On behalf of Mubashar Sheikh Executive Director Global Health Workforce.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
Tracking national portfolios and assessing results Sub-regional Workshop for GEF Focal Points in West and Central Africa June 2008, Douala, Cameroon.
Investment Planning and Implementation for Low Emissions Development LEDS Global Partnership Annual Workshop Punta Cana, Dominican Republic October 14-16,
Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.
Meeting of AcademyHealth Members Joseph Antos, Ph.D., Chair Coalition for Health Services Research June 8, 2008.
Record Keeping Studies – Love ‘Em or Leave ‘Em National Science Foundation Division of Science Resources Statistics International Conference on Establishment.
Tracking the Shortfall in TB Research Funding Javid Syed Treatment Action Group (TAG)
APHA 2001 Conference Atlanta, Georgia 22 October 2001 Does resource allocation meet policy priorities? Tania Dmytraczenko, Ph.D. Patricia Hernandez, M.D.,
Research and Innovation Research and Innovation Research and Innovation Research and Innovation Horizon 2020 The EU Framework Programme for Research and.
Eastern Caribbean Countries Health System and Private Sector Assessments 2011 Lisa Tarantino USAID’s Health Systems 20/20 Caribbean & Strengthening Health.
Global Public Health Informatics Partnerships: Vision, Challenges and Progress Sherrilynne Fuller, Ph.D;* Debra Revere, MLIS, MA;* Ann Marie Kimball MD,
#innovate4health July 20,
Account Management Overview
EFC Members annual survey: - For the record: the framework
2017/18 SANSA Annual Performance Plan
Technical Consultation: Folate Status in Women and NTD Risk-Reduction
Legal Aspects Related to Brownfield Regeneration
Proposal Development Services
Associate Director for Research, Education and Marine Operations
Boston’s Payment in Lieu of Tax Program:
U.S. Global Health Funding (Actual): United Nations Population Fund (UNFPA), FY 2001-FY 2017 Request In Millions NOTES: FY13 includes the effects of sequestration.
Southern Obesity Summit Senior Program Officer
  FOR HIV PREVENTION RESEARCH & DEVELOPMENT RESOURCE TRACKING
2018 OSEP Project Directors’ Conference
Pay For Success: An Invitation to Learn More
U.S. Global Health Funding for the United Nations Population Fund (UNFPA), FY 2001-FY 2014 (Actual) In Millions NOTES: FY 2014 is President’s Budget Request.
The role of Territorial Cooperation in IWT and integrated planning
Innovative Medicines Initiative:
U.S. Funding (Actual) for the United Nations Population Fund (UNFPA), FY 2001 – FY 2019 Request In Millions NOTES: FY13 includes the effects of sequestration.
U.S. Global Health Funding (Enacted): United Nations Population Fund (UNFPA), FY 2001-FY 2016 Request In Millions NOTES: FY13 includes the effects of sequestration.
U.S. Funding (Enacted) for the United Nations Population Fund (UNFPA), FY 2001 – FY 2019 Request In Millions NOTES: FY13 includes the effects of sequestration.
WMO Congress XV Strengthening National and Regional Partnerships in Disaster Risk Reduction Maryam Golnaraghi, Ph.D. Chief, Natural Disaster Prevention.
Division of AIDS Office of the Director Workforce Operations,
Parliament: Hearing on Liquid Fuels Charter
Creating Working Partnerships that Increase Power
U.S. Funding (Enacted) for the United Nations Population Fund (UNFPA), FY 2001 – FY 2020 Request In Millions NOTES: FY13 includes the effects of sequestration.
U.S. Funding (Actual) for the United Nations Population Fund (UNFPA), FY 2001 – FY 2020 Request In Millions NOTES: FY13 includes the effects of sequestration.
Multisectoral Response
Developing a Financial Sustainability Plan for Cambodia
National Immunization Conference 2005 March 22, 2005 ~ Washington D.C.
Presentation transcript:

tracking microbicide funding Polly F. Harrison, PhD Director, Alliance for Microbicide Development Satellite Meeting: Resource Tracking & Priority Setting XV International AIDS Conference, Bangkok 11 July 2004- 9:30-11:30am

methodology (overview) track 3 major sectors US public sector international public sector philanthropic sector methodological style methodological structure record “actual” annual expenditures estimate current fiscal year expenditures Microbicide funding flows from 3 major sectors: US and international public sectors and the philanthropic sector. Currently, “Big Pharma” does not contribute financially to microbicide development. Methodology style- gather funding information by: Identification of knowledgeable sources, Personal contact Persistence + charm Methodological structure

overview of funding for microbicide R&D by sector, 2002 Here is a snapshot of what microbicide funding looked like in 2002. In 2002, the microbicide funding by sector was as follows: US public sector: $75.3 million Int’l public sector: $49.4 million Philanthropic sector: $17.1 million We would like to note that this pie chart does not capture the investment, mostly leveraging internal resources, by small companies and other institutions, however the reality is this is difficult to quantify. [refer to chart for any questions regarding specifics]

overview of funding for microbicide R&D by sector, 1997-end 2003 (cumulative) From 1997- 2003 the support for microbicide R&D has been the following: US public sector- $334.4 million International public sector- $69.5 million Philanthropic sector- $79.7 million Again noting the absence of investment, mostly leveraging internal resources, by small companies and other institutions. [refer to chart for any questions regarding specifics]

The next 3 slides are to give you an idea of our current methodological structure for tracking microbicide funding. Please bear with me as you probably will not be able to see the detail of each slide.

what we think we have estimates for FY2004 US public sector $88.8 million int’l public sector $34.8 million philanthropic sector $19.4 million estimated total = $143.0 million Now onto Fiscal year 2004: Preliminary estimates for Fiscal year 2004 are the following: US public sector $88.8 million Int’l public sector $34.8 million Philanthropic sector $19.4 million Estimated grand total of $143 million [refer to chart for any questions regarding specifics]

future plans for microbicide tracking transition from macro to micro level basic science preclinical development clinical development microbicide education, advocacy, & policy development establish formal annual report of findings (blueprint? coordination w/ vaccines?) [read from slide] In addition, the Alliance has begun to work on answering the question: what the field needs for funding support?

what we need: respondents & cost ranges preclinical-3 developers, range $400k-4M phase 1-16 developers, range $300k-4M phase 2-4 developers, range $2M-5M phase 3-10 developers, range $9M-50M This is an overview of our preliminary conversations with key developers within the microbicide field. We hope to integrate this data into a forecast model soon.

challenges & issues international tracking gaps timely congressionally-mandated reports to Congress (US public sector) need for standardized reporting back from all sectors

next steps for tracking investment in new HIV prevention technologies increased collaboration among institutions tracking investments countries funding prevention technologies, & philanthropic organizations funding prevention technologies, start to track their spending options being explored to improve estimates of industry funding all funders provide information on their funding allocations by type of activity & geographic location

acknowledgments Franka N. des Vignes, PhD Program Officer Trisha L. Lamphear, MPH Research Associate Jana C. Bowcut, MPH Cecilia D. Fox Administrative Associate Pamela Norick Senior Legislative & Policy Adviser The work of the Alliance has been made possible by the dedication of its participants & contributions from the: • William & Flora Hewlett Foundation • International Partnership for Microbicides • Moriah Fund • Rockefeller Foundation • Bill & Melinda Gates Foundation through the • Global Microbicide Project & the generosity of private contributors.

for more information www.microbicide.org or contact the Alliance directly: 8484 Georgia Avenue, Suite 940 Silver Spring, MD, USA 20910 tel: 301-587-9690; fax: 301-588-8390 email: info@microbicide.org